| 產(chǎn)品編號(hào) | bs-4895R |
| 英文名稱(chēng) | Rabbit Anti-PIRH2 antibody |
| 中文名稱(chēng) | 泛素連接酶抗體 |
| 別 名 | Androgen receptor N terminal interacting protein; Androgen receptor N-terminal-interacting protein; ARNIP; CH-rich-interacting match with PLAG1; CHIMP; E3 ubiquitin-protein ligase Pirh2; hARNIP; hPirh2; p53 induced protein with a RING H2 domain; p53-induced RING-H2 protein; PIRH2E; PIRH2F; PRO1996; RCHY1; Ring finger and CHY zinc finger domain containing 1 E3 ubiquitin protein ligase; RING finger and CHY zinc finger domain-containing protein 1; RING finger protein 199; RNF199; ZFP 363; Zinc finger protein 363; ZN363_HUMAN. |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 泛素 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Human,Mouse (predicted: Rat,Pig,Sheep,Cow,Dog,Horse) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,Flow-Cyt=2ug/Test,ICC/IF=1:50,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 30kDa |
| 細(xì)胞定位 | 細(xì)胞核 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PIRH2: 31-130/261 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Pirh2 has p53-induced ubiquitin-protein ligase activity, promoting p53 degradation. The protein physically interacts with p53 and the resulting degradation of p53 renders Pirh2 an oncogenic protein as the loss of p53 function contributes to malignant tumor development. The gene encoding for the protein maps to chromosome 4q21.1 and transcription of this gene is regulated by p53. Pirh2 expression decreases the level of p53 and a decrease of endogenous Pirh2 expression ups p53 levels. Pirh2 is therefore considered, together with MDM2, to be acting as a negative regulator of p53 function. Function: Mediates E3-dependent ubiquitination and proteasomal degradation of target proteins, including p53/TP53, HDAC1 and CDKN1B. Preferentially acts on tetrameric p53/TP53. Increases AR transcription factor activity (By similarity). Contributes to the regulation of CDKN1B and p53/TP53 levels, and thereby contributes to the regulation of the cell cycle progression. Subunit: Monomer and homodimer. Interacts with AR, p53/TP53, MDM2, HDAC1, KAT5, PLAG1, PLAGL2, CDKN1B, COPE, UBE2D2 and GORAB/NTKLBP1 (By similarity). Subcellular Location: Nucleus (By similarity). Nucleus speckle (By similarity). Cytoplasm (By similarity). Tissue Specificity: Detected in testis, liver, kidney and heart. Post-translational modifications: Subject to ubiquitination and proteasomal degradation (By similarity). Similarity: Contains 1 CHY-type zinc finger. Contains 1 CTCHY-type zinc finger. Contains 1 RING-type zinc finger. SWISS: Q96PM5 Gene ID: 25898 Database links: Entrez Gene: 771726 Chicken Entrez Gene: 25898 Human Entrez Gene: 68098 Mouse Omim: 607680 Human SwissProt: Q96PM5 Human SwissProt: Q9CR50 Mouse Unigene: 48297 Human Unigene: 159453 Mouse Pirh2通過(guò)負(fù)反饋調(diào)控p53的轉(zhuǎn)錄激活和細(xì)胞生長(zhǎng)抑制功能； Pirh2蛋白是一個(gè)新發(fā)現(xiàn)的泛素蛋白連接酶，受到p53的誘導(dǎo)調(diào)控表達(dá)，可促進(jìn)p53蛋白的泛素化降解。目前多用于肺癌的研究。 |
| 產(chǎn)品圖片 |
Sample:Kidney(Mouse)Lysate at 40 ug
Primary: Anti-PIRH2(bs-4895R)at 1/300 dilution
Secondary: IRDye800CW Goat Anti-RabbitIgG at 1/20000 dilution
Predicted band size: 30kD
Observed band size: 30kD
Sample:
Lane 1: Mouse Stomach tissue lysates
Lane 2: Mouse Spleen tissue lysates
Primary: Anti-PIRH2 (bs-4895R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 30 kDa
Observed band size: 30 kDa
Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-PIRH2 Polyclonal Antibody, Unconjugated(bs-4895R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: human glioma tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-PIRH2 Polyclonal Antibody, Unconjugated(bs-4895R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Hela cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (PIRH2) polyclonal Antibody, Unconjugated (bs-4895R) 1:50, 90 minutes at 37°C; followed by a conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.
Blank control（black line）:Hela.
Primary Antibody (green line): Rabbit Anti-PIRH2 antibody (bs-4895R)
Dilution:2ug/Test;
Secondary Antibody（white blue line）: Goat anti-rabbit IgG-FITC
Dilution: 0.5ug/Test.
Isotype control（orange line）: Normal Rabbit IgG
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20℃, The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
